GlassScriptPhysician profile
Elliot Mark Epner
NPI 1083622559
$16,242.78
in general payments reported to CMS, 2019-2025
54 companies · $270 in 2025
The $270 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,954 · 2020: $3,271 · 2021: $1,744 · 2022: $366 · 2023: $4,952 · 2024: $687 · 2025: $270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,286 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,600 · Education: $22.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,285.61 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,600.00 |
| Education | $22.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $2,705.15 | 2019-2023 | Tazverik |
| Celgene Corporation | $2,363.42 | 2019-2023 | Reblozyl |
| Leadiant Biosciences, INC. | $2,250.00 | 2020 | |
| Eisai INC. | $961.58 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $814.47 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $784.75 | 2019-2024 | Tagrisso, Lynparza, Calquence |
| Janssen Biotech, INC. | $674.52 | 2019-2025 | Rybrevant, Carvykti, Erleada |
| Takeda Pharmaceuticals U.S.A., INC. | $630.34 | 2019-2020 | |
| Lilly USA, LLC | $384.29 | 2019-2023 | Jaypirca, Verzenio |
| Astellas Pharma US INC | $376.45 | 2019-2023 | Xospata, Padcev |
| E.R. Squibb & Sons, L.L.C. | $345.37 | 2019-2023 | Opdivo |
| Incyte Corporation | $320.59 | 2019-2023 | Pemazyre, Monjuvi, Jakafi |
| Merck Sharp & Dohme LLC | $281.41 | 2019-2023 | Keytruda, Welireg, Lynparza |
| Exelixis INC. | $274.43 | 2019-2025 | Cabometyx |
| Alexion Pharmaceuticals, INC. | $266.87 | 2019-2023 | Ultomiris |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $252.15 | 2019-2023 | Libtayo |
| Amgen INC. | $241.98 | 2019-2023 | Lumakras, Nplate, Vectibix |
| Pfizer INC. | $211.58 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $208.12 | 2019-2023 | |
| Menarini Silicon Biosystems, INC. | $193.56 | 2023-2024 | Cellsearch |
| Beigene USA, INC. | $177.92 | 2023-2024 | Brukinsa |
| Seagen INC. | $177.78 | 2022-2023 | Padcev, Adcetris, Tukysa |
| Genzyme Corporation | $131.41 | 2019-2023 | |
| Genentech USA, INC. | $130.51 | 2019-2023 | Venclexta, Polivy, Lunsumio |
| Glaxosmithkline, LLC. | $82.86 | 2022-2023 | Ojjaara, Shingrix |
| Progenics Pharmaceuticals, INC. | $80.73 | 2023 | Pylarify |
| Karyopharm Therapeutics INC. | $73.69 | 2020-2023 | Xpovio |
| Gilead Sciences, INC. | $72.51 | 2021-2023 | Trodelvy |
| Pharmaessentia USA Corporation | $60.86 | 2023 | Besremi |
| Daiichi Sankyo INC. | $58.79 | 2022-2023 | Enhertu |
| Jazz Pharmaceuticals INC. | $57.91 | 2023 | |
| Tesaro, INC. | $56.07 | 2019 | |
| Puma Biotechnology, INC. | $47.31 | 2019-2023 | |
| Pharmacyclics LLC, An Abbvie Company | $43.57 | 2019-2023 | Imbruvica |
| Abbvie INC. | $37.67 | 2023 | |
| Taiho Oncology, INC. | $34.93 | 2023 | |
| Tersera Therapeutics LLC | $33.56 | 2023 | Xermelo |
| Foundation Medicine, INC. | $33.22 | 2023 | Foundationone Cdx |
| Aveo Pharmaceuticals, INC. | $29.26 | 2023 | Fotivda |
| Sanofi-Aventis U.S. LLC | $24.49 | 2019 | |
| Mirati Therapeutics, INC. | $23.57 | 2023 | Krazati |
| Emd Serono, INC. | $22.82 | 2019 | |
| Spectrum Pharmaceuticals INC. | $22.50 | 2023 | Rolvedon |
| Blueprint Medicines Corporation | $22.06 | 2023 | Ayvakit |
| Clovis Oncology, INC. | $21.47 | 2019 | |
| Morphosys, US INC. | $21.30 | 2023 | Monjuvi |
| Coherus Oncology, INC. | $20.43 | 2023 | |
| Organon LLC | $18.56 | 2023 | Ontruzant |
| Amneal Pharmaceuticals LLC | $16.91 | 2023 | Avastin |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.71 | 2023 | |
| Recordati_rare_diseases_inc. | $14.52 | 2023 | Sylvant |
| Rigel Pharmaceuticals, INC. | $14.29 | 2023 | Rezlidhia, Tavalisse |
| Adaptive Biotechnologies Corporation | $13.02 | 2023 | Clonoseq |
| Janssen Pharmaceuticals, INC | $8.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elliot Epner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.